logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

New Agents For The Treatment Of Acute Lymphoblastic Leukemia 1st Edition Tim Eden Auth

  • SKU: BELL-2245922
New Agents For The Treatment Of Acute Lymphoblastic Leukemia 1st Edition Tim Eden Auth
$ 31.00 $ 45.00 (-31%)

0.0

0 reviews

New Agents For The Treatment Of Acute Lymphoblastic Leukemia 1st Edition Tim Eden Auth instant download after payment.

Publisher: Springer-Verlag New York
File Extension: PDF
File size: 3.66 MB
Pages: 338
Author: Tim Eden (auth.), Vaskar Saha, Pamela Kearns (eds.)
ISBN: 9781441984586, 1441984585
Language: English
Year: 2011
Edition: 1

Product desciption

New Agents For The Treatment Of Acute Lymphoblastic Leukemia 1st Edition Tim Eden Auth by Tim Eden (auth.), Vaskar Saha, Pamela Kearns (eds.) 9781441984586, 1441984585 instant download after payment.

New Agents for the Treatment of Acute Lymphoblastic Leukaemia (ALL), examines the strategies for the use of new agents as well as possible targets of therapy in this disease. Though associated with high cure rates, relapsed disease has a poor outcome. Moreover, therapy is unduly prolonged and toxic. For over 4 decades, no new drugs have been available and now we have a surfeit. The challenge is to design trials to evaluate the potential efficacy of non-targeted therapy in a disease with good outcome. An increasing number of pathways, amenable to targeted therapy are also being identified. The heterogeneity of ALL suggests that targeted therapy at the moment will need to be tailored to the patient. How then can such drugs be evaluated within conventional clinical trials? These are the crossroads we have reached in acute lymphoblastic leukaemia and this book discusses and proposes some solutions to these issues.

Related Products